IL1A and plasma cell myeloma: A phase II clinical trial investigated the effect of anakinra, an IL-1 receptor antagonist (IL-1Ra), in patients with indolent multiple myeloma showed that anakinra decreased the myeloma proliferation rate.163,164 IL-1Ra blocks the signaling pathway activated by both IL-1α and IL-1β.